Substance Use, Violence, and Antiretroviral Adherence: A Latent Class Analysis of Women Living with HIV in Canada

Abstract

We used latent class analysis to identify substance use patterns for 1363 women living with HIV in Canada and assessed associations with socio-economic marginalization, violence, and sub-optimal adherence to combination antiretroviral therapy (cART). A six-class model was identified consisting of: abstainers (26.3%), Tobacco Users (8.81%), Alcohol Users (31.9%), ‘Socially Acceptable’ Poly-substance Users (13.9%), Illicit Poly-substance Users (9.81%) and Illicit Poly-substance Users of All Types (9.27%). Multinomial logistic regression showed that women experiencing recent violence had significantly higher odds of membership in all substance use latent classes, relative to Abstainers, while those reporting sub-optimal cART adherence had higher odds of being members of the poly-substance use classes only. Factors significantly associated with Illicit Poly-substance Users of All Types were sexual minority status, lower income, and lower resiliency. Findings underline a need for increased social and structural supports for women who use substances to support them in leading safe and healthy lives with HIV.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112(3):178–93.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21):948–52.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Slawson G, Milloy M, Balneaves L, Simo A, Guillemi S, Hogg R, et al. High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav. 2015;19(1):120–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10(4):731–6.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Rosen M, Black A, Arnsten J, Goggin K, Remien R, Simoni J, et al. Association between use of specific drugs and antiretroviral adherence: findings from MACH 14. AIDS Behav. 2013;17(1):142–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103(8):1457–67.

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15(1):193.

    Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29(2):117–27.

    Article  PubMed  Google Scholar 

  10. 10.

    Health Canada. Canadian Alcohol and Drug Use Monitoring Survey: Summary of Results for 2011. 2011. http://www.hc-sc.gc.ca/hc-ps/drugs-drogues/stat/_2011/summary-sommaire-eng.php-share.

  11. 11.

    Kalichman SC, Grebler T, Amaral CM, McNerney M, White D, Kalichman MO, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med. 2014;21(5):811–20.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Chander LB, Moore R. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection (1999). J Acquir Immune Defic Syndromes. 2006;43(4):411.

    Article  Google Scholar 

  13. 13.

    Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis (1999). J Acquir Immune Defic Syndromes. 2009;52(2):180.

    Article  Google Scholar 

  14. 14.

    Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retrovir. 2010;26(5):511–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Bonn-Miller MO, Oser ML, Bucossi MM, Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2014;37(1):1–10.

    Article  PubMed  Google Scholar 

  16. 16.

    Lake S, Kerr T, Capler R, Shoveller J, Montaner J, Milloy MJ. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. Int J Drug Policy. 2017;42:63–70.

    Article  PubMed  Google Scholar 

  17. 17.

    Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362(9392):1267–74.

    Article  PubMed  Google Scholar 

  18. 18.

    Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996–2004. PLoS ONE. 2009;4(2):e4445.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci. 2011;88(21):940–7.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Machtinger E, Wilson T, Haberer JE, Weiss D. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8):2091–100.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Borwein A, Chan K, Palmer A, Miller C, Montaner J, Hogg R. Violence among a cohort of HIV-positive women on antiretroviral therapy in British Columbia, Canada. Oral session presented at 1st International Workshop on HIV and Women 2011, January.

  22. 22.

    Trimble DD, Nava A, McFarlane J. Intimate partner violence and antiretroviral adherence among women receiving care in an urban Southeastern Texas HIV clinic. J Assoc Nurses AIDS Care. 2013;24(4):331–40.

    Article  PubMed  Google Scholar 

  23. 23.

    Gruskin L, Gange SJ, Celentano D, Schuman P, Moore JS, Zierler S, et al. Incidence of violence against HIV-infected and uninfected women: findings from the HIV Epidemiology Research (HER) Study. J Urban Health. 2002;79(4):512–24.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Bedimo AL, Kissinger P, Bessinger R. History of sexual abuse among HIV-infected women. Int J STD AIDS. 1997;8(5):332–5.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Shannon K, Kerr T, Strathdee SA, Shoveller J, Montaner JS, Tyndall MW. Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers. BMJ. 2009;339:2939–47.

    Article  Google Scholar 

  26. 26.

    El-Bassel N, Gilbert L, Wu E, Go H, Hill J. HIV and intimate partner violence among methadone-maintained women in New York City. Soc Sci Med. 2005;61(1):171–83.

    Article  PubMed  Google Scholar 

  27. 27.

    El-Bassel N, Witte S, Wada T, Gilbert L, Wallace J. Correlates of partner violence among female street-based sex workers: substance abuse, history of childhood abuse, and HIV risks. AIDS Patient Care STDs. 2001;15(1):41–51.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Pearce ME, Christian WM, Patterson K, Norris K, Moniruzzaman A, Craib KJP, et al. The cedar project: historical trauma, sexual abuse and HIV risk among young aboriginal people who use injection and non-injection drugs in two Canadian cities. Soc Sci Med. 2008;66(11):2185–94.

    Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Berger. Workable sisterhood: the political journey of stigmatized women with HIV/AIDS. Princeton: Princeton University Press; 2010.

    Google Scholar 

  30. 30.

    Logie C, James L, Tharao W, Loutfy M. HIV, gender, race, sexual orientation, and sex work: a qualitative study of intersectional stigma experienced by HIV-positive women in Ontario, Canada. PLoS Med. 2011;8(11):e1001124.

    Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Azim T, Bontell I, Strathdee SA. Women, drugs and HIV. Int J Drug Policy. 2015;26(1):S16–21.

    Article  PubMed  Google Scholar 

  32. 32.

    Campbell JC, Baty M, Ghandour RM, Stockman JK, Francisco L, Wagman J. The intersection of intimate partner violence against women and HIV/AIDS: a review. Int J Injury Control Saf Promot. 2008;15(4):221–31.

    CAS  Article  Google Scholar 

  33. 33.

    Hatcher AM, Smout EM, Turan JM, Christofides N, Stöckl H. Intimate partner violence and engagement in HIV care and treatment among women: a systematic review and meta-analysis. AIDS. 2015;29(16):2183–94.

    Article  PubMed  Google Scholar 

  34. 34.

    Schafer KR, Brant J, Gupta S, Thorpe J, Winstead-Derlega C, Pinkerton R, et al. Intimate partner violence: a predictor of worse HIV outcomes and engagement in care. AIDS Patient Care STDs. 2012;26(6):356–65.

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Machtinger E, Haberer J, Wilson T, Weiss D. Recent trauma is associated with antiretroviral failure and HIV transmission risk behavior among HIV-positive women and female-identified transgenders. AIDS Behav. 2012;16(8):2160–70.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Women’s Health. 2011;20(7):991–1006.

    Article  Google Scholar 

  37. 37.

    Sullivan KA, Messer LC, Quinlivan EB. Substance abuse, violence, and HIV/AIDS (SAVA) syndemic effects on viral suppression among HIV positive women of color. AIDS Patient Care STDs. 2015;29(S1):S42–8.

    Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Singer M. A dose of drugs, a touch of violence, a case of AIDS: conceptualizing the SAVA syndemic. Free Inq Creative Sociol. 1996;24(2):99–110.

    Google Scholar 

  39. 39.

    Singer M. AIDS and the health crisis of the US urban poor; the perspective of critical medical anthropology. Soc Sci Med. 1994;39(7):931–48.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423–41.

    Article  PubMed  Google Scholar 

  41. 41.

    Batchelder AW, Lounsbury DW, Palma A, Carrico A, Pachankis J, Schoenbaum E, et al. Importance of substance use and violence in psychosocial syndemics among women with and at-risk for HIV. AIDS Care. 2016;28(10):1316–20.

    Article  PubMed Central  Google Scholar 

  42. 42.

    Koblin BA, Grant S, Frye V, Superak H, Sanchez B, Lucy D, et al. HIV sexual risk and syndemics among women in three urban areas in the United States: analysis from HVTN 906. J Urban Health. 2015;92(3):572–83.

    Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Dale S, Cohen M, Weber K, Cruise R, Kelso G, Brody L. Abuse and resilience in relation to HAART medication adherence and HIV viral load among women with HIV in the United States. AIDS Patient Care STDs. 2014;28(3):136–43.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Collins LM, Lanza ST. Latent class and latent transition analysis: with applications in the social, behavioral, and health sciences. Hoboken: Wiley; 2013.

    Google Scholar 

  45. 45.

    Sunderland M, Chalmers J, McKetin R, Bright D. Typologies of alcohol consumption on a saturday night among young adults. Alcoholism. 2014;38(6):1745–52.

    Article  PubMed  Google Scholar 

  46. 46.

    Noor SW, Ross MW, Lai D, Risser JM. Use of latent class analysis approach to describe drug and sexual HIV risk patterns among injection drug users in Houston, Texas. AIDS Behav. 2014;18(3):276–83.

    Article  PubMed  Google Scholar 

  47. 47.

    McCarty-Caplan D, Jantz I, Swartz J. MSM and drug use: a latent class analysis of drug use and related sexual risk behaviors. AIDS Behav. 2014;18(7):1339–51.

    Article  PubMed  Google Scholar 

  48. 48.

    Newcomb ME, Ryan DT, Greene GJ, Garofalo R, Mustanski B. Prevalence and patterns of smoking, alcohol use, and illicit drug use in young men who have sex with men. Drug Alcohol Depend. 2014;141:65–71.

    Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Lanza ST, Bray BC. Transitions in drug use among high-risk women: an application of latent class and latent transition analysis. Adv Appl Stat Sci. 2010;3(2):203–35.

    PubMed  PubMed Central  Google Scholar 

  50. 50.

    Loutfy M, Greene S, Kennedy VL, Lewis J, Thomas-Pavanel J, Conway T, et al. Establishing the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS): operationalizing Community-based Research in a Large National Quantitative Study. BMC Med Res Methodol. 2016;16(1):101–10.

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Loutfy M dPA, O’Brien N, Thomas-Pavanel J, Carter A, Proulx-Boucher K, Beaver K, Nicholson V, Colley G, Sereda P, Hogg RS, Kaida A, CHIWOS Research Team. The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS): an evaluation of women-centred HIV care (WCC). 5th International Workshop on HIV and Women; Seattle, WAFebruary 21-22nd, 2015.

  52. 52.

    Israel BA, Schulz AJ, Parker EA, Becker AB. Review of community-based research: assessing partnership approaches to improve public health. Annu Rev Public Health. 1998;19(1):173–202.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Raphael D. Social determinants of health: Canadian perspectives. 2nd ed. Toronto: Canadian Scholars’ Press; 2009.

    Google Scholar 

  54. 54.

    Benoit C, Shumka L. Gendering the population health perspective: fundamental determinants of women’s health. Final report prepared for the Women’s Health Research Network. Vancouver, BC; 2007.

  55. 55.

    De Reus LA, Few AL, Blume LB. Multicultural and critical race feminisms: theorizing families in the third wave. Sourceb Fam Theory Res. 2005. doi:10.4135/9781412990172.n18.

    Google Scholar 

  56. 56.

    Webster K, Carter A, Proulx-Boucher K, Dubuc D, Nicholson V, Beaver K, et al. Strategies for recruiting women living with HIV in community-based research: Lessons from Canada Progress in Community Health Partnerships: Research, Education, and Action. Accepted.

  57. 57.

    Palamar JJ, Davies S, Ompad DC, Cleland CM, Weitzman M. Powder cocaine and crack use in the United States: an examination of risk for arrest and socioeconomic disparities in use. Drug Alcohol Dependence. 2015;149:108–16.

    Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Statistics Canada. Low income lines, 2013-2014: Update Ottawa, Canada: Statistics Canada; 2013.

  59. 59.

    Wagnild G, Young H. Development and psychometric validation of the resilience scale. J Nurs Meas. 1993;1:165–78.

    CAS  PubMed  Google Scholar 

  60. 60.

    Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16(2):269–77.

    Article  PubMed  Google Scholar 

  61. 61.

    Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Model. 2007;14(4):671–94.

    Article  Google Scholar 

  62. 62.

    Lanza ST, Dziak JJ, Huang L, Xu S, Collins LM. PROC LCA & PROC LTA user’s guide (Version 1.3.2). University Park: The Methodology Center, Pennsylvania State University; 2015.

  63. 63.

    Akaike H. Factor analysis and AIC. Psychometrika. 1987;52(3):317–32.

    Article  Google Scholar 

  64. 64.

    Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2):461–4.

    Article  Google Scholar 

  65. 65.

    Bozdogan H. Model selection and Akaike’s information criterion (AIC): the general theory and its analytical extensions. Psychometrika. 1987;52(3):345–70.

    Article  Google Scholar 

  66. 66.

    Sclove SL. Application of model-selection criteria to some problems in multivariate analysis. Psychometrika. 1987;52(3):333–43.

    Article  Google Scholar 

  67. 67.

    Vermunt JK. Latent class modeling with covariates: two improved three-step approaches. Polit Anal. 2010;18(4):450–69.

    Article  Google Scholar 

  68. 68.

    Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007;21(9):1175–83.

    Article  PubMed  Google Scholar 

  69. 69.

    Wasserstein RL, Lazar NA. The ASA’s statement on p-values: context, process, and purpose. The American Statistician. 2016.

  70. 70.

    Rothman KJ. Epidemiology: an introduction. New York: Oxford University Press; 2012.

    Google Scholar 

  71. 71.

    Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63(2):179–86.

    Article  PubMed  Google Scholar 

  72. 72.

    Hutton HE, McCaul ME, Chander G, Jenckes MW, Nollen C, Sharp VL, et al. Alcohol use, anal sex, and other risky sexual behaviors among HIV-infected women and men. AIDS Behav. 2013;17(5):1694–704.

    Article  PubMed  Google Scholar 

  73. 73.

    Chander Josephs J, Fleishman J, Korthuis P, Gaist P, Hellinger J, et al. Alcohol use among HIV-infected persons in care: results of a multi-site survey. HIV Med. 2008;9(4):196–202.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  74. 74.

    Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV + men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med. 2007;30(5):371–83.

    Article  PubMed  PubMed Central  Google Scholar 

  75. 75.

    Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896–903.

    Article  PubMed  PubMed Central  Google Scholar 

  76. 76.

    Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Gerstoft J, et al. Mortality attributable to smoking among HIV-1–infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727–34.

    Article  PubMed  Google Scholar 

  77. 77.

    Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent tobacco smoking is associated with poor HIV medical outcomes among HIV-infected individuals in New York. AIDS Behav. 2016. doi:10.1007/s10461-015-1273-x.

    PubMed  PubMed Central  Google Scholar 

  78. 78.

    Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. JAIDS J Acquir Immune Defic Syndromes. 2004;35(1):38–45.

    Article  Google Scholar 

  79. 79.

    Reid JL, Hammond D, Rynard VL, Burkhalter R. Tobacco use in Canada: patterns and trends. 2015th ed. Waterloo: Propel Centre for Population Health Impact, University of Waterloo; 2015.

    Google Scholar 

  80. 80.

    Kuo I, Golin CE, Wang J, Haley DF, Hughes J, Mannheimer S, et al. Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend. 2014;139:93–9.

    Article  PubMed  PubMed Central  Google Scholar 

  81. 81.

    Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD. Methamphetamine use, sexual activity, patient–provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004–2006. AIDS Care. 2009;21(5):575–82.

    Article  PubMed  Google Scholar 

  82. 82.

    Kapadia F, Vlahov D, Wu Y, Cohen MH, Greenblatt RM, Howard AA, et al. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse. 2008;34(2):161–70.

    Article  PubMed  Google Scholar 

  83. 83.

    Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Supplement 3):S272–8.

    Article  PubMed  Google Scholar 

  84. 84.

    Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on HAART, irrespective of adherence level. J Acquir Immune Defic Syndromes. 2010;55(4):460.

    CAS  Article  Google Scholar 

  85. 85.

    Günthard HF, Saag MS, Benson CA, Rio C, Eron JJ, Gallant JE. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA Panel. JAMA. 2016;2016:316.

    Google Scholar 

  86. 86.

    Brizay U, Golob L, Globerman J, Gogolishvili D, Bird M, Rios-Ellis B, et al. Community-academic partnerships in HIV-related research: a systematic literature review of theory and practice. J Int AIDS Soc. 2015;18(1):19354.

    Article  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Parashar S, Palmer AK, O’Brien N, Chan K, Shen A, Coulter S, et al. Sticking to it: the effect of maximally assisted therapy on antiretroviral treatment adherence among individuals living with HIV who are unstably housed. AIDS Behav. 2011;15(8):1612.

    Article  PubMed  PubMed Central  Google Scholar 

  88. 88.

    Maru DS-R, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, et al. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav. 2008;12(2):284–93.

    Article  PubMed  Google Scholar 

  89. 89.

    Macalino GE, Hogan JW, Mitty JA, Bazerman LB, DeLong AK, Loewenthal H, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS. 2007;21(11):1473–7.

    Article  PubMed  Google Scholar 

  90. 90.

    Altice FL, Maru DS-R, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45(6):770–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  91. 91.

    Lappalainen L, Nolan S, Dobrer S, Puscas C, Montaner J, Ahamad K, et al. Dose–response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction. 2015;110(8):1330–9.

    Article  PubMed  PubMed Central  Google Scholar 

  92. 92.

    Vancouver Coastal Health. Insite - Supervised Injection Site 2016. http://supervisedinjection.vch.ca.

  93. 93.

    British Columbia Ministry of Health. Integrated models of primary care and mental health & substance use care in the community: literature review and guiding document. Vancouver: British Columbia Ministry of Health; 2012.

    Google Scholar 

  94. 94.

    British Columbia Centre of Excellence for Women’s Health. Women-centred harm reduction: gendering the national framework. Vancouver: British Columbia Centre of Excellence for Women’s Health; 2012.

    Google Scholar 

  95. 95.

    Kamarulzaman A, Altice FL. The challenges in managing HIV in people who use drugs. Curr Opin Infect Dis. 2015;28(1):10.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS) Research Team would like to especially thank all of the women living with HIV who participate in this research. We also thank the entire national team of Co-Investigators, Collaborators, and Peer Research Associates. We would like to acknowledge the national Steering Committee, the three provincial Community Advisory Boards, the national CHIWOS Aboriginal Advisory Board, and our partnering organizations for supporting the study, especially those who provide interview space and support to our Peer Research Associates.

Funding

CHIWOS is funded by the Canadian Institutes of Health Research (CIHR, MOP111041); the CIHR Canadian HIV Trials Network (CTN 262); the Ontario HIV Treatment Network (OHTN); and the Academic Health Science Centres (AHSC) Alternative Funding Plans (AFP) Innovation Fund. AC received support from a CIHR Doctoral Award. AdP received support from Fonds de Recherche du Quebéc – Santé (FRQS) (Chercheur-boursier clinicien – Junior 1). AK received salary support through a Tier 2 Canada Research Chair in Global Perspectives on HIV and Sexual and Reproductive Health. M-JM is supported in part by the United States National Institutes of Health (R01-DA0251525), a Scholar Award from the Michael Smith Foundation for Health Research and a New Investigator Award from CIHR. His institution has received unstructured funding to support his research from NG Biomed, Ltd.

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to Angela Kaida.

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Additional research team members and affiliated institutions are listed below in Appendix.

Appendix

Appendix

Chiwos Research Team

British Columbia Aranka Anema (University of British Columbia), Denise Becker (Positive Living Society of British Columbia), Lori Brotto (University of British Columbia), Allison Carter (British Columbia Centre for Excellence in HIV/AIDS and Simon Fraser University), Claudette Cardinal (Simon Fraser University), Guillaume Colley (British Columbia Centre for Excellence in HIV/AIDS), Erin Ding (British Columbia Centre for Excellence), Janice Duddy (Pacific AIDS Network), Nada Gataric (British Columbia Centre for Excellence in HIV/AIDS), Robert S. Hogg (British Columbia Centre for Excellence in HIV/AIDS and Simon Fraser University), Terry Howard (Positive Living Society of British Columbia), Shahab Jabbari (British Columbia Centre for Excellence), Evin Jones (Pacific AIDS Network), Mary Kestler (Oak Tree Clinic, BC Women’s Hospital and Health Centre), Andrea Langlois (Pacific AIDS Network), Viviane Lima (British Columbia Centre for Excellence in HIV/AIDS), Elisa Lloyd-Smith (Providence Health Care), Melissa Medjuck (Positive Women’s Network), Cari Miller (Simon Fraser University), Deborah Money (Women’s Health Research Institute), Valerie Nicholson (Simon Fraser University), Gina Ogilvie (British Columbia Centre for Disease Control), Sophie Patterson (Simon Fraser University), Neora Pick (Oak Tree Clinic, BC Women’s Hospital and Health Centre), Eric Roth (University of Victoria), Kate Salters (Simon Fraser University), Margarite Sanchez (ViVA, Positive Living Society of British Columbia), Jacquie Sas (CIHR Canadian HIV Trials Network), Paul Sereda (British Columbia Centre for Excellence in HIV/AIDS), Marcie Summers (Positive Women’s Network), Christina Tom (Simon Fraser University, BC), Clara Wang (British Columbia Centre for Excellence), Kath Webster (Simon Fraser University), Wendy Zhang (British Columbia Centre for Excellence in HIV/AIDS).

Ontario Rahma Abdul-Noor (Women’s College Research Institute), Jonathan Angel (Ottawa Hospital Research Institute), Fatimatou Barry (Women’s College Research Institute), Greta Bauer (University of Western Ontario), Kerrigan Beaver (Women’s College Research Institute), Anita Benoit (Women’s College Research Institute), Breklyn Bertozzi (Women’s College Research Institute), Sheila Borton (Women’s College Research Institute), Tammy Bourque (Women’s College Research Institute), Jason Brophy (Children's Hospital of Eastern Ontario), Ann Burchell (Ontario HIV Treatment Network), Allison Carlson (Women’s College Research Institute), Lynne Cioppa (Women’s College Research Institute), Jeffrey Cohen (Windsor Regional Hospital), Tracey Conway (Women’s College Research Institute), Curtis Cooper (Ottawa Hospital Research Institute), Jasmine Cotnam (Women’s College Research Institute), Janette Cousineau (Women’s College Research Institute), Marisol Desbiens (Women’s College Research Institute), Annette Fraleigh (Women’s College Research Institute), Brenda Gagnier (Women’s College Research Institute), Claudine Gasingirwa (Women’s College Research Institute), Saara Greene (McMaster University), Trevor Hart (Ryerson University), Shazia Islam (Women’s College Research Institute), Charu Kaushic (McMaster University), Logan Kennedy (Women’s College Research Institute), Desiree Kerr (Women’s College Research Institute), Maxime Kiboyogo (McGill University Health Centre), Gladys Kwaramba (Women’s College Research Institute), Lynne Leonard (University of Ottawa), Johanna Lewis (Women’s College Research Institute), Carmen Logie (University of Toronto), Shari Margolese (Women’s College Research Institute), Marvelous Muchenje (Women’s Health in Women’s Hands), Mary (Muthoni) Ndung'u (Women’s College Research Institute), Kelly O’Brien (University of Toronto), Charlene Ouellette (Women’s College Research Institute), Jeff Powis (Toronto East General Hospital), Corinna Quan (Windsor Regional Hospital), Janet Raboud (Ontario HIV Treatment Network), Anita Rachlis (Sunnybrook Health Science Centre), Edward Ralph (St. Joseph’s Health Care), Sean Rourke (Ontario HIV Treatment Network), Sergio Rueda (Ontario HIV Treatment Network), Roger Sandre (Haven Clinic), Fiona Smaill (McMaster University), Stephanie Smith (Women’s College Research Institute), Tsitsi Tigere (Women’s College Research Institute), Wangari Tharao (Women’s Health in Women’s Hands), Sharon Walmsley (Toronto General Research Institute), Wendy Wobeser (Kingston University), Jessica Yee (Native Youth Sexual Health Network), Mark Yudin (St-Michael’s Hospital).

Québec Dada Mamvula Bakombo (McGill University Health Centre), Jean-Guy Baril (Université de Montréal), Nora Butler Burke (University Concordia), Pierrette Clément (McGill University Health Center), Janice Dayle, (McGill University Health Centre), Danièle Dubuc, (McGill University Health Centre), Mylène Fernet (Université du Québec à Montréal), Danielle Groleau (McGill University), Ken Montheith (COCQ-SIDA), Marina Klein (McGill University Health Centre), Carrie Martin (Native Women’s Shelter of Montreal), Lyne Massie, (Université de Québec à Montréal), Brigitte Ménard, (McGill University Health Centre), Nadia O'Brien (McGill University Health Centre and Université de Montréal), Joanne Otis (Université du Québec à Montréal), Doris Peltier (Canadian Aboriginal AIDS Network), Alie Pierre, (McGill University Health Centre), Karène Proulx-Boucher (McGill University Health Centre), Danielle Rouleau (Centre Hospitalier de l’Université de Montréal), Édénia Savoie (McGill University Health Centre), Cécile Tremblay (Centre Hospitalier de l’Université de Montréal), Benoit Trottier (Clinique l’Actuel), Sylvie Trottier (Centre Hospitalier Universitaire de Québec), Christos Tsoukas (McGill University Health Centre).

Other Canadian provinces or international jurisdictions Jacqueline Gahagan (Dalhousie University), Catherine Hankins (University of Amsterdam and McGill University), Renee Masching (Canadian Aboriginal AIDS Network), Susanna Ogunnaike-Cooke (Public Health Agency of Canada).

All other CHIWOS Research Team Members who wish to remain anonymous.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Carter, A., Roth, E.A., Ding, E. et al. Substance Use, Violence, and Antiretroviral Adherence: A Latent Class Analysis of Women Living with HIV in Canada. AIDS Behav 22, 971–985 (2018). https://doi.org/10.1007/s10461-017-1863-x

Download citation

Keywords

  • Substance use
  • Violence
  • Antiretroviral adherence
  • HIV/AIDS
  • Women